SCHEMBL4302491

SCHEMBL4302491

CN(C(=O)OC(C)(C)C)c1cc2cc(B3OC(C)(C)C(C)(C)O3)ccc2cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.43
BACE2 Q9Y5Z0 1/20 0.43
USP30 Q70CQ3 2/20 0.42
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
DGAT1 O75907 1/20 0.39
TTK P33981 1/20 0.39
AAK1 Q2M2I8 2/20 0.39
HIF1A Q16665 3/20 0.35
GSK3B P49841 2/20 0.33
DYRK1A Q13627 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
LPL P06858 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
F2 P00734 1/20 0.31
F11 P03951 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
FFAR1 O14842 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303492 0.84 LIPG (0.36) DGAT1HIF1AGSK3BIRAK4LPL
SCHEMBL1181140 0.84 DGAT1 (0.48) BACE1BACE2USP30PRMT5WDR77
SCHEMBL29827999 0.84 DGAT1 (0.48) BACE1BACE2USP30PRMT5WDR77
SCHEMBL25146980 0.83 BACE1 (0.44) BACE1BACE2USP30PRMT5WDR77
SCHEMBL29845293 0.83 BACE1 (0.44) BACE1BACE2USP30PRMT5WDR77
SCHEMBL21566125 0.81 USP30 (0.43) BACE1BACE2USP30PRMT5WDR77
SCHEMBL1180889 0.79 USP30 (0.50) BACE1BACE2USP30PRMT5WDR77
SCHEMBL25347617 0.78 USP30 (0.47) BACE1BACE2USP30PRMT5WDR77
SCHEMBL30657958 0.77 PRMT5 (0.55) BACE1BACE2USP30PRMT5WDR77
SCHEMBL26653703 0.77 PRMT5 (0.55) BACE1BACE2USP30PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 BACE1 3107/4885BACE2 2601/4885USP30 4723/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 BACE1 2314/4885BACE2 1974/4885USP30 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.